[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557379":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":22,"responsibleParty":29,"collaborators":22,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":22,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":22,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":22,"overallStatus":49,"whyStopped":22,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":22},{"fullName":5,"class":6},"He Eye Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DQS group","EXPERIMENTAL","Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co.,Ltd., Osaka, Japan) six times per day for 4 weeks",[13],"Drug: 3% Diquafosol tetrasodium",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","3% Diquafosol tetrasodium","3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye",[9],[21],"Diquas",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Jiayan Chen","CONTACT","18304019060","cjy100009@outlook.com",{"type":30,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100557379","effects-of-3-diquafosol-on-tear-film-and-vision-related-quality-of-life-in-orthokeratology-lens-related-dry-eye-100557379",false,"NCT06537349","Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye","Inclusion Criteria:\n\n* Age 8-18 years old\n* Wearing corneal shape mirror more than one year and at least eight hours every night\n* Myopia -5.50 to -1.00 D, astigmatism \\\u003C 1.75 D, or curvature between 41.00 and 46.00D, astigmatism \\\u003C -0.75D, and best corrected visual acuity ≥1.0.\n* Diagnosis of dry eye: patients complained of dry eye, foreign body sensation, burning sensation, fatigue, discomfort, envy, subjective symptom such as vision fluctuation; (a) OSDI questionnaire score \\>13 points, and (b) NITBUT \\\u003C10 s or (c) ocular surface dyeing assessment \\> 5 corneal spots\u002Fmore than nine conjunctival spots.\n* Participants were able to use eye drops as required, complete examinations, and return to the hospital for follow-up examinations within the specified time to complete follow-up.\n\nExclusion Criteria:\n\n* Suffering from allergic or autoimmune disease associated with dry eye of the participants are not suitable for wearing OK lens\n* Pathological changes in the corneal rim\n* Eyelid rim lesions, cornea, uveitis, retina and other systemic diseases may affect the ocular surface. Examples include severe ocular surface diseases (Sjögren's syndrome, allergic conjunctivitis, ocular papules, conjunctival chafing, conjunctival scarring, and chemical damage);\n* Received any dry eye treatment within 14 days prior to the start of this study or continued use of other topical eye drops that would affect the results of the study.\n* Have received any other eye treatment or surgery","ALL","8 Years","18 Years",{"count":41,"type":42},30,"ESTIMATED","INTERVENTIONAL",[45],"NA","Investigate the effect of 3% Diquafosol on tear film and vision-related quality of life in dry eye patients wearing orthokeratology lenses(OK lens), and to provide reference for clinical treatment.This prospective, open label study will include 60 eyes of 30 OK lens related dry eye patients.Participants will receive 3% Diquafosol ophthalmic solution. The dosage for both drugs will be one drop, six times per day for 4 weeks. Pediatric Refractive Error Profiletear(PREP), tear film lipid layer (TFLL),non-invasive breakup time (NITBUT), corneoconjunctival staining score (CS), tear meniscus height (TMH), objective visual quality,ocular surface disease index (OSDI) will be assessed and compared at baseline, day-14, and day-28",[48],"Dry Eye","NOT_YET_RECRUITING","2024-08-08",{"date":52,"type":53},"2024-08-12","ACTUAL",{"date":55,"type":42},"2024-08-15",{"date":57,"type":42},"2024-12-31",{"name":5,"class":6}]